(B) The Edwards Sapien™ (Edwards Lifesciences, Inc., CA, USA) valve is a balloon-expandable, bovine pericardial interventional aortic valve.
Over the last two decades, Edwards Lifesciences has demonstrated that it knows how to maintain leadership through innovation of tissue heart valves. Edwards remains the dominant force in surgical ...
Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this ...
Edwards Lifesciences Corp.’s posted fourth quarter results slightly ahead of expectations, but indicated that the first quarter of 2025 might not be as bright. The company expects growth for both its ...
Edwards Lifesciences reported better-than-expected fourth-quarter sales, driven by its transcatheter aortic valve replacement (TAVR) devices, to finish 2024 on an upbeat but cautious note after a ...
Edwards Lifesciences Corporation (NYSE:EW), a leading medical technology company specializing in heart valve therapies and critical care technologies with a market capitalization of $44.9 billion, has ...
Edwards Lifesciences stock popped Wednesday on strong sales of its TAVR procedures, leading to a top- and bottom-line beat.
Why it matters: Edwards reached an inflection point in 2024 with transcatheter aortic valve, or TAVR, sales slowing, while the launch of and revenue from new transcatheter mitral and tricuspid ...
Edwards Lifesciences Corporation (NYSE:EW) holds around 50% market share in the $7 billion transcatheter aortic valve replacement (TAVR) market. Its products in the sector are responsible for ...
Edwards Lifesciences Corporation (NYSE:EW) holds around 50% market share in the $7 billion transcatheter aortic valve replacement (TAVR) market. Its products in the sector are responsible for ...